Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipella Pharmaceuticals Inc LIPO

Healthcare Biotechnology
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Its lead product candidates include LP-10, LP-310 and LP-410. LP-10 is the development name of its reformulation of tacrolimus specifically optimized for topical... see more

Recent & Breaking News (NDAQ:LIPO)

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

GlobeNewswire August 27, 2024

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

GlobeNewswire August 22, 2024

Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference

GlobeNewswire August 21, 2024

Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial

GlobeNewswire August 12, 2024

Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

GlobeNewswire August 1, 2024

Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules

GlobeNewswire August 1, 2024

Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients

GlobeNewswire July 29, 2024

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

GlobeNewswire May 31, 2024

Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 29, 2024

Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b

GlobeNewswire May 21, 2024

Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise

GlobeNewswire April 17, 2024

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

GlobeNewswire April 5, 2024

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

GlobeNewswire April 3, 2024

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

GlobeNewswire March 5, 2024

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

GlobeNewswire February 20, 2024

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

GlobeNewswire December 20, 2023

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

PR Newswire November 10, 2023

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

PR Newswire October 25, 2023

Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

PR Newswire October 24, 2023

Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference

Accesswire October 23, 2023